MYD88 and myelodysplastic syndrome: Lack of MYD88 mutation in LPL/WM, however, predicts worse outcome with higher risk of transformation, therapy-related myelodysplastic syndrome, as well as shorter time to transformation compared to MYD88 mutated patients [5, 11, 12].